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Abstract 
We aimed to evaluate the relationship between Circulating tumor Cells (CTCs) and plasma Cell-
free DNA (cfDNA) on one side and a comprehensive range of 18F-fluorodeoxyglucose (FDG)-
PET/CT-derived parameters on the other side in chemotherapy-naïve patients with advanced 
NSCLC. 
Methods: Among the seventy-nine patients included in the VeriStrat® trial, evaluating the role of 
pretreatment circulating tumor markers as predictors of prognosis in chemotherapy-naïve patients 
with advanced NSCLC, we recruited all subjects submitted to FDG-PET/CT for clinical reasons 
at our institution before the inclusion in the trial (and thus just before chemotherapy). For each 
patient a peripheral blood sample was collected at baseline for the evaluation of CTCs and 
cfDNA. CTCs were isolated by size using a filtration-based device and then morphologically 
identified and enumerated; cfDNA was isolated from plasma and quantified by a qPCR method 
using human telomerase reverse transcriptase (hTERT). The following FDG-PET/CT-derived 
parameters were computed: maximum diameter (dmax) of the primary lesion (T), of the greater 
lymph node (N) and of the greater metastatic (M) lesion; SUVmax, SUVmean, size-incorporated 
SUVmax (SIMaxSUV), Metabolic Tumor Volume, Total Lesion Glycolysis. All parameters 
were independently measured for T, N and M. The associations among CTCs, cfDNA and 
FDG-PET/CT derived parameters were evaluated by multivariate-analysis. Patients were divided 
in two groups according to the presence of either limited metastatic involvements (M1a or M1b 
due to extra-thoracic lymph nodes, M1bLympho) or disseminated metastatic disease 
(M1bDisseminated). Presence (B+) or absence (B-) of metabolically-active bone lesions was also 
recorded for each patient and patients’ subgroups were compared. 
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Results: Thirty-seven patients recruited in the VeriStrat® trial matched our PET-based criteria (24 
males; age 64.5 ± 8.1 years). M-SUVmax was the only variable independently associated with 
baseline cfDNA levels (p=0.016). Higher levels of cfDNA were detected in the subgroup of 
patients with metabolically active bone lesions (p=0.02) while no difference was highlighted when 
comparing patients with more limited metastatic disease with patients with M1bDisseminated. 
Conclusions: The correlation of cfDNA amount with tumor metabolism, but not with metabolic 
tumor volume at regional or distant levels, suggests that cfDNA might better reflect tumor 
biological behavior/aggressiveness rather than tumor burden in metastatic NSCLC.  
 
Keywords: positron emission tomography, circulating tumor markers, non-small cell lung cancer, 
metabolic tumor volume, maximum standardized uptake value 
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Introduction 
Despite the identification of CTCs and cfDNA as biomarkers potentially able to provide 
clinically relevant information in cancer patients, at present, their identification is not routinely 
envisioned in the clinical practice (1). Indeed, incomplete understanding of the specific role of 
these biomarkers in different tumor types as well as unsolved technical issues still limit their 
systematic assessment in the clinical setting (1). Several studies have demonstrated a prognostic 
value of CTC enumeration  or cfDNA levels in different malignancies including non-small cells 
lung cancer (NSCLC) (2-5).  
In particular, a significant role of baseline CTCs or cfDNA determinations  before first-line 
therapy has been highlighted in some tumor types, and the presence of increased levels of 
circulating tumor markers in advanced malignancies has been demonstrated to correlate with 
poor patients’ prognosis (6).  However, whether this observation merely reflects their role as 
tumor burden indicators or might reveal other biological mechanisms associated with tumor 
aggressiveness is still a matter of debate (1).  
In recent years imaging procedures have emerged as meaningful prognostic indicators in 
oncology and previous studies have investigated the interplay between circulating tumor markers 
and imaging biomarkers (6). In this framework FDG-PET/CT may be an ideal tool to elucidate 
the relevance of circulating tumor markers in relation to tumor burden and biology (6). The 
majority of the available studies investigating the relationship between FDG-PET and circulating 
tumor markers have been carried out in colon and breast cancer patients (6, 7,8) while data in 
NSCLC patients are presently limited (9, 10). FDG-PET/CT has a recognized high accuracy in 
NSCLC patients both in early and advanced stage of disease. Similarly, intensity of FDG uptake 
and thus tumor metabolism has an established prognostic value as being linked to aggressive 
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tumor biology (11) and metastatic potential in NSCLC patients (12). To date only one 
prospective study has been performed by Nygaard and colleagues (10) to assess the relationship 
between cfDNA and FDG-PET in patients with advanced NSCLC before receiving 
chemotherapy. This study did not highlight any correlation between tumor DNA and FDG-PET-
assessed tumor burden; however, only the whole body metabolic tumor volume (MTV) and 
average glycolytic volume (TGL) were included in the analysis, while other potentially 
prognostic variables derived from FDG-PET images were not considered.  
Moreover, since different biological and prognostic behaviors can be hypothesized for primary 
lesions, lymph-node and distant metastases, a detailed investigation of the interplay between 
circulating tumor markers and PET-derived parameters should take into account these different 
components, especially in advanced stage patients. Based on these considerations, the present 
study aimed at evaluating, by a multivariate approach, the relationship between CTCs or cfDNA 
on one side and a comprehensive range of PET-derived parameters (both at the loco-regional and 
distant lesion-levels) on the other side in a homogenous population of chemotherapy-naïve 
patients with advanced NSCLC. 
 
Methods 
Patient’s enrollment.  
The study has been approved by the institutional review board and all subjects signed an informed 
consent form. 
Seventy-nine patients with newly diagnosed advanced NSCLC candidate for first-line 
chemotherapy were enrolled into a prospective study (13) at the Lung Cancer Unit, IRCCS AOU 
San Martino-IST, Genova, Italy from October 2012 to October 2015. The trial aimed to test the 
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value of VeriStrat® (a pretreatment blood-based test of circulating tumor markers) as predictor of 
prognosis after first line platinum-based combination chemotherapy in advanced NSCLC 
(ClinicalTrials.gov Identifier: NCT02055144). The inclusion criteria comprised histologically 
confirmed NSCLC stage IV, no previous treatment, and aged above 18 years. All the patients 
underwent first-line standard of care treatment for metastatic NSCLC represented by platinum-
based combination chemotherapy: cisplatin or carboplatin in association with pemetrexed for 
adenocarcinoma or with gemcitabine for the squamous histotype, respectively (14).  
FDG-PET evaluation was not mandatory; however, a subgroup of patients underwent FDG-
PET/CT examinations for standard clinical indications (mainly for staging or restaging 
completion) at the time of inclusion in the study and before receiving chemotherapy. For each 
patient a peripheral blood sample was collected at baseline (before treatment) for the evaluation of 
circulating biomarkers. 
The present study has been approved by Ethics committee of IRCCS AOU San Martino - IST 
(ID#TrPo11.003) and all enrolled subjects provided a written informed consent including the 
analysis of circulating biomarkers. Among the patients enrolled in this study, only the patients who 
underwent FDG-PET in our Institution just before the start of chemotherapy were included in the 
specific analysis of correlation between circulating biomarkers and PET parameters. 
 
CTC isolation  
CTC were isolated from 3mL of whole peripheral blood (EDTA tube) by the ScreenCell®Cyto kit 
(ScreenCell,Paris, France) according to the manufacturer’s procedure. Briefly, circulating cells are 
isolated by size using a polycarbonate filter containing randomly distributed calibrated pores 
(7.5±0.36 μm) throughout the membrane. After filtration, the filter is then released on the slide 
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and processed for enumeration and morphology. The isolated non-hematologic circulating cells 
with malignant features were defined as CTCs and morphologically identified and enumerated 
under, light microscope, according to the following criteria: Nuclear size greater than or equal to 
20m, high nucleo-cytoplasmic ratio (≥ 0.75), dense hyper chromatic nucleus, and irregular 
nuclear membrane. 
 
Circulating free DNA (cfDNA) isolation and quantification  
Four mL of peripheral blood were collected in EDTA-containing tubes. Such tubes were processed 
by centrifugation at 1600 rpm for 15 minutes in order to isolate plasma; a further centrifugation 
was performed to eliminate any cell contamination and the resulting plasma was stored at -80°C.  
cfDNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), 
according to the protocol. The purified cfDNA from 400 µl of plasma was eluted in a final volume 
of 50 µl buffer TE 0,1X and stored at -20°C. The quantification of cfDNA was performed by 
quantitative real-time quantitative PCR (qPCR), using hTERT (ThermoFisher Scientific, 
Wilmington, DE, USA) single copy gene. Each qPCR was carried out in a final reaction volume 
of 10 µl, consisting of 5 µl of TaqMan Universal Mastermix (ThermoFisher Scientific), 1 µl of 
assay and 4 µl of cfDNA. Each cfDNA sample was run in duplicates, and the plate included a 
positive and a negative control. The calibration curve was calculated based on a dilution series of 
a standard DNA (Promega, Madison, WI, USA): 1, 10, 100, 1000, 10.000, 100.000 copy number 
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FDG-PET/CT acquisition  
All the patients underwent preparation and FDG-PET/CT according to European guidelines (15) 
and data were acquired using a 16-slices PET/CT hybrid system (Biograph 16, Siemens Medical 
Solutions, Knoxville TN, USA). Briefly, patients fasted overnight prior to the intravenous 
administration of 350-450 MBq of FDG, which was performed in a quiet room, with the patient 
lying in a recumbent position and instructed not to move. Blood glucose was measured before 
tracer injection, as to ensure blood glucose levels <160 mg/dl. To minimize artifacts caused by the 
urinary tract, patients were asked to drink 500-1,000 mL of water 1 h prior to image acquisition 
and to empty the bladder just before the acquisition start. No urinary bladder catheterization was 
used. Imaging started 60±15 minutes after intravenous tracer administration (patient with longer 
FDG uptake time were excluded). The technical parameters of the 16-detector row, helical CT 
scanner included a gantry rotation speed of 0.5 s and table speed of 24 mm per gantry rotation. 
The PET component of the combined imaging system had an axial view of 16.2 cm per bed 
position, with an interslice spacing of 3.75 mm. The transaxial field of view and pixel size of the 
reconstructed PET images were 58.5 cm and 4.57 mm, respectively, with a matrix size of 128×128. 
Unenhanced low-dose CT was performed at 140 kV and 40 mA for attenuation correction of 
emissive data and anatomical localization of PET dataset. Emissive scan was performed in in 3D 
mode, shortly after CT acquisition, with a 3-min acquisition per bed position. PET sinograms were 
reconstructed by means of ordered-subset expectation maximization (OSEM) iterative 
reconstruction algorithm (three iterations, eight subsets). Scan was performed starting from the 
orbital plane on to the mid-thigh, except for the cases where the clinical history demanded a whole 
body, vertex-to-toes scan.  
Images Analysis 
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For all FDG-PET/CT scans the following parameters were measured: 1. maximum diameter 
(dmax) of the primary lesion (T); 2. dmax of the greater lymph node (N); 3. dmax of the greater 
metastatic (M) lesions; 4. Maximum Standardized uptake value (SUVmax); 5. Average SUV 
(SUVmean); 6. size-incorporated SUVmax (SIMaxSUV); 7. Metabolic Tumor Volume (MTV) 8. 
Total Lesion Glycolysis (TLG). SUVmax, SUVmean, SIMaxSUV, MTV, and TGL were 
independently measured for T, N and M. In particular, SIMaxSUV was defined as the product of 
the greatest diameter (mm) of the primary lesion (for T) or of the greatest lesion (for N and M) and 
the SUVmax of the same lesion (16, 17); MTV was assessed by means Syngo Siemens workstation 
and was computed by using SUVmax ≥ 2.5 as thresholds (10); TLG for T, N, M was computed as 
MTVxSUVmean. Finally, the patients were divided in two groups according to the presence of 
either limited metastatic involvements (patients with M1a or classified as M1b due to extra 
thoracic lymph nodes only, M1bLympho) or disseminated metastatic disease (all other patients with 
M1b, M1bDisseminated) on FDG-PET/CT scan. Similarly, presence (B+) or absence (B-) of 
metabolically active bone lesions was recorded for each patient. 
Statistical Analysis 
The associations among CTCs, cfDNA and FDG-PET/CT derived parameters were evaluated by 
multivariate analysis (Statistical Package for the Social Sciences, SPSS version 17).  T-test was 
performed to evaluate the difference in CTCs or cfDNA in patients with M1a plus M1bLympho with 
respect to patients M1bDisseminate as well as in B+ and B- subgroups respectively. The Mann-
Withney unpaired test was used to compare independent variables. P<0.05 was regarded as 
significant. 
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Results 
Patients 
Thirthy-seven out of 79 patients recruited in the VeriStrat® trial matched our PET-based criteria. 
Median age was 64.5 ± 8.1 years (range: 51-80); male/female ratio was 24/13; 19 patients were 
current smokers, while 16 were former smokers and 2 were never-smokers. Histological subtypes 
were adenocarcinoma (n=28) and squamous cell carcinoma (n=9). All the patients excluding one 
showed metabolically active metastatic lesions. In particular, 12 patients were classified as M1a,  
23 patients were classified as M1bDisseminated, and one patient was classified as M1b due to the 
presence of extra thoracic lymph nodes (M1bLympho). In addition, 13 out of 37 patients had 
metabolically active bone lesions. See Table1 for patients’ characteristics. 
 
Circulating Tumor Markers 
Whole blood withdrawals for cfDNA and CTC evaluations were collected from advanced NSCLC 
patients at baseline before platinum-based combination chemotherapy. The median baseline CTC 
count of 6 CTCs/3mL of blood (range: 0-47 CTCs/3mL), and the median cfDNA of 101 hTERT 
copy number (range: 16-1604) were identified as the most appropriate cut-offs for comparative 
studies with FDG-PET/CT derived parameters. CTC count was not significantly associated with 
any PET-derived parameters by Mann-Withney test. The only statistically significant association 
was observed for cfDNA and M-SUVmax (P=0.003). Indeed patients with cfDNA hTERT copy 
number above the median level exhibited a higher median M-SUVmax value as compared to those 
with cfDNA above the median level (Table2). 
 
PET/CT-derived predictors of circulating tumor markers 
by Univ of CA San Diego on April 30, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
At multivariate analysis, M-SUVmax was the only variable independently associated with baseline 
cfDNA levels (p=0.016). No further correlations were highlighted between cfDNA levels as well 
as CTC number and all the others PET-derived parameters. Table 2 summarizes the results of the 
multivariate analysis. Notably, higher levels of cfDNA were detected in the subgroup of patients 
with metabolically active bone lesions (p=0.02) while no difference was highlighted when 
comparing patients with more limited metastatic disease (M1a + M1blympho) with patients with 
M1bDisseminated (regardless of the anatomic topography of the lesions) (Figure1). No significant 
difference was observed in the CTC number when comparing patients with more limited metastatic 
disease and patients with disseminated lesions (M1bdisseminated); similarly, no significant difference 
in the CTC number was observed in patients with or without metastatic bone involvement. Figure 





The present study evaluated the correlation between CTC number or cfDNA level and PET-
derived parameters, both at the loco-regional or distant lesion levels in a homogenous population 
of chemotherapy-naïve patients with advanced NSCLC.  Our results reported a positive correlation 
between high baseline level of cfDNA and tumor metabolic activity. Since neither MTV nor 
SIMaxSUV (which include a volumetric assessment) showed any relationship with plasma 
concentration of cfDNA and only SUVmax was significantly associated with this circulating 
biomarker, it is conceivable that cfDNA might better reflect tumor metabolism and biological 
behavior rather than tumor burden in metastatic NSCLC.  
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A previous study by Nygaard and colleagues estimated the tumor burden in terms of MTV and 
TLG in a similar setting(10).  Although higher MTV as well as cfDNA level were associated with 
a significantly shorter overall survival, no correlation between cfDNA and the PET-derived 
parameters was found. These controversial results might be explained by the fact that only two 
PET-derived parameters (MTV and TGL) were taken into account. Indeed, different cut-offs for 
MTV computation have been proposed but none of them has been validated in this setting and 
overall consensus about the best PET-based indicator is presently lacking. Previous studies have 
assessed the relationship of circulating tumor markers and FDG-PET-CT in different cancers (4, 
18). In this framework the majority of studies have been carried out in other malignancies, 
especially in metastatic breast and colon cancer (18). In recent years, a study in NSCLC patients 
evaluated the change in CTC counts and its relationship with FDG-PET in patients treated with 
chemotherapy for relapsed disease (4). However, the authors were unable to find a SUVmax cut-
off predicting response of CTC to treatment and SUVmax demonstrated a trend in predicting 
change in CTCs only after allocating patients in responders and non-responders. Similarly, a 
retrospective evaluation of NSCLC patients who underwent FDG-PET-CT imaging and CTC 
detection before therapy was previously carried out by Nair et al (9). Again the study demonstrated 
a weak correlation with SUVmax and no correlation with tumor diameter. However both studies 
were multi-centers and the results of the analyses might have been influenced by the effect of 
different PET scanners. Notably, only in the study of Nair and colleagues the FDG-PET inter-
scanner calibration was performed (9). Our experience follows the same path but in a different and 
more homogeneous study population.  Indeed while, we only considered chemotherapy naïve 
advanced NSCLC patients, in the study by Nair and colleagues, early-stage patients were mostly, 
but not exclusively, included. To summarize, questionable and mostly negative results on this topic 
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emerged from the few available studies in NSCLC likely uncovering some technical limits such 
as the different (and often heterogeneous) patients’ populations, the use of diverse PET scanners 
and the lack of gold standard indicators of tumor burden and/or aggressiveness by means of PET.  
In the present study an independent correlation between SUVmax and cfDNA was disclosed by 
means of a multivariate analysis which included a wide range of PET/CT derived parameters 
determining patients’ tumor burden and biology (T, N and M). Specifically, the SUVmax of the 
metastatic lesions was the only independent predictor of cfDNA levels. The presence of a 
significant correlation between cfDNA and tumor metabolism of the metastatic lymph nodes rather 
than the primary tumor is in keeping with the hypothesis that circulating tumor markers might be 
strongly related to the metastatic potential of different tumor types (19). In particular, when we 
took into account the subset of patients with bone metastases, the relevance of cfDNA in defining 
the biological behavior of the tumor was further highlighted. Higher levels of cfDNA were 
observed in the subgroup of patients with metabolically active bone lesions, while no difference 
was found for the other disseminated metastatic lesions regardless of their anatomical topography. 
As it has been demonstrated that high FDG uptake may relate to the tumor metastatic potential 
(12, 20), the identification of the association between cfDNA and the active bone lesions may 
represent a step forward in the understanding of the mechanisms underlying metastasis and tropism 
in NSCLC.  
Notably, while cfDNA correlated with tumor metabolism, no association was conversely found 
between CTCs and PET-derived parameters in the present population.  
Previous investigations have suggested that cfDNA and CTCs may provide complementary 
information about tumor biology. In particular, CTCs derive as intact cells shed from the primary 
or metastatic tumor sites, while cfDNA is released from different sources including apoptosis, 
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necrosis, phagocytosis and lysis of tumor cells (1).  These different biological features and the 
limited number of patients might be partly responsible for the discordant results, thus preventing 
to draw definitive conclusions about the role of CTCs in NSCLC metabolism. 
The present study has some drawbacks: more specifically, it is a single-center study including a 
limited number of patients recruited within a clinical trial in which the FDG-PET/CT was not 
mandatory; as a consequence, only patients referred to FDG-PET/CT for specific clinical reasons 
before the inclusion in the study were investigated and some of the patients’ characteristics might 
have affected the analysis. Therefore, the present results should be confirmed within a full 
prospective design including FDG-PET/CT examination as part of the trial. 
In conclusion, although additional studies are required to propose a more accurate modeling 
regarding the interplay among tumor metabolism, circulating tumor markers and tumor 
aggressiveness, the present preliminary data support the role of cfDNA as an indicator of tumor 
biology/aggressiveness rather than of tumor burden in advanced NSCLC patients before 
chemotherapy initiation.  The identification and a deeper understanding of clinically reliable 
noninvasive biomarkers may help identify potential unresponsive NSCLC patients before 
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Figure 1. 
Histograms showing free circulating tumor DNA (cfDNA) levels in subgroups of patients 
according to the presence/absence of disseminated metastasis or metabolically active 
bone lesions. Higher cfDNA levels were detected in the subgroup of patients with 
metabolically active bone lesions while no difference was highlighted when comparing 
patients with more limited metastatic disease (M1a + M1b just due to extra-thoracic 
lymph nodes) with patients with disseminated M1b disease (regardless of the anatomic 
topography of the lesions).  
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Figure 2 
Two representative examples of patients enrolled in present study. Panel A and B show 
two coronal and trans-axial sections of the FDG-PET/CT scan of a 73 years old female 
with stage IV NSCLC (adenocarcinoma; cfDNA 462 hTERT copy number ; 3 
CTC/3mL). Sections in panel A include the highly FDG-concentrating primary lesion in 
the left lung (dmax 49 mm; SUV max 7.2; MTV 82.4 ml) while panel B shows a small 
bone lesion in the left scapula (dmax 10 mm; SUV max 5.7; MTV 5 ml). Panel C and D 
correspond to the FDG-PET/CT scan of a 70 years old male with stage IV NSCLC 
(adenocarcinoma; cfDNA 113 hTERT copy number ; 3 CTC/3mL). Sections in panel C 
include the moderately FDG-concentrating primary lesion in the right lung (dmax 83 
mm; SUV max 4.9; MTV 193.2 ml) while panel D shows multiple mediastinal and 
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cervical lymph nodes (dmax of the greated lymph node 30 mm; SUV max 3.2; MTV 65 
ml). Patient displayed in panel A and B showed lower tumor burden (as expressed by the 
MTV) but higher SUVmax and cfDNA levels with respect to patient displayed in panel C 
and D. CfDNA, free circulating tumor DNA; SUVmax, Standardized Uptake Value, 
MTV, Metabolic Tumor Volume). 
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Table 1. Patients' Demographics and Clinical Characteristics 
  
    
Demography    
Age  (years; mean, range) 64.5 (51–80)   
Gender  (m/f) 24/13   
    
Stage at diagnosis  Histology  
IIIb 1 adenocarcinoma   28 
IV  36 squamous cell carcinoma   9 
    
TNM  FDG avid bone lesions  
T  yes 13 
x 4 no 24 
1 3   
2 15 Smoking habit  
3 3 yes 19 
4 12 no 2 
N  former 16 
x 1   
0 7 ECOG PS at baseline  
1 0 0 9 
2 22 1 27 
3 7 2 1 
M    
0 1 Prior Surgery  
1a Controlater lung 3 yes  5 
1a Lung/Pleural disseminated  9 no 32 
1b extrathoracic Lymph nodes 1   
1b distant metastasis 23 Prior Radiotherapy  
  yes 1 
    no 36 
Unless otherwise stated, results are reported as numbers of patients   
ECOG PS, Eastern Cooperative Oncology Group Performance Status  
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Table 2. Multivariate Analysis       
18F-FDG PET/CT parameters  Mean±standard deviation p 
T Size 54.4±35 mm 0.175 
 SUV max  12.4±4.5 g/ml 0.076 
 SUV mean 6.3±2.9 g/ml 0.994 
 SIMaxSUV 652±594 0.472 
 MTV 179±172 ml 0.463 
 TGL 554±595 g 0.313 
N Size 26.4±10.4 mm 0.083 
 SUV max  12.7±12.5 g/ml 0.318 
 SUV mean 5±2.4 g/ml 0.307 
 SIMaxSUV 261±144 0.463 
 MTV 22.7±21.10 ml 0.371 
 TGL 191±169 g 0.572 
M Size 28.3±23.9 mm 0.313 
 SUV max  6.3±4.6 g/ml 0.016* 
 SUV mean 4.1±2.1 g/ml 0.294 
 SIMaxSUV 180±148 0.231 
 MTV 28.1±31.0 ml 0.201 
  TGL 180±31.7 g 0.401 
SUV, standardized uptake 
value    
SIMaxSUV was defined  as the product of the greatest diameter (mm) of the primary lesion 
(for T) or of the greatest lesion (for N and M) and the SUVmax of the same lesion 
MTV, Metabolic Tumor 
Volume    
TLG, Total Lesion Glycolysis computed as MTVxSUVmean  
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